<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527342</url>
  </required_header>
  <id_info>
    <org_study_id>SUCARD</org_study_id>
    <nct_id>NCT03527342</nct_id>
  </id_info>
  <brief_title>Sahlgrenska Cardiomyopathy Project</brief_title>
  <official_title>Sahlgrenska University Hospital Cardiomyopathy Project: Mapping and Diagnosis of Cardiomyopathies to Enable Early and Specific Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal.&#xD;
&#xD;
      Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP)&#xD;
      including in depth clinical and molecular phenotyping to enable earlier and specific&#xD;
      treatment. The project will serve as:&#xD;
&#xD;
        1. resource for diagnostic and therapeutic trials&#xD;
&#xD;
        2. common biomaterial bank&#xD;
&#xD;
        3. resource for detailed molecular analyses on patients' biomaterials and patient specific&#xD;
           symptoms and examination results&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>2018-2028</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Progression in biomarker NT-proBNP</measure>
    <time_frame>2018-2028</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes over time in presence of autoantibodies</measure>
    <time_frame>2018-2028</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease activity evaluated by positron-emissions-tomography computed tomography (PET-CT)</measure>
    <time_frame>2018-2028</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Disease activity evaluated by magnetic resonance imaging (MRI)</measure>
    <time_frame>2018-2028</time_frame>
  </other_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Dilated Cardiomyopathies</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Restrictive Cardiomyopathy</condition>
  <condition>Arrhythmogenic Right Ventricular Cardiomyopathy</condition>
  <condition>Myocarditis</condition>
  <condition>Sarcoidosis With Myocarditis</condition>
  <condition>Giant Cell Myocarditis</condition>
  <condition>Amyloidosis; Heart (Manifestation)</condition>
  <arm_group>
    <arm_group_label>Dilated Cardiomyopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Myocarditis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcoidosis Heart</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Giant Cell Myocarditis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Amyloidosis Heart</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertrophic Cardiomyopathies</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Left Ventricular Myocardial Noncompaction Cardiomyopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Arrhythmogenic Right Ventricular Cardiomyopathies</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients are all patients referred to Sahlgrenska University Hospital, Gothenburg,&#xD;
        Sweden with a cardiomyopathy diagnose.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary cardiomyopathies including hereditary and inflammatory dilated&#xD;
             cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, left&#xD;
             ventricular non-compaction cardiomyopathy, arrhythmogenic right ventricular&#xD;
             cardiomyopathy, myocarditis, giant cell myocarditis, sarcoidosis and amyloidosis&#xD;
             engaging the heart&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with other preexisting cardiac diseases such as significant valvular, ischemic&#xD;
             or pericardial disease before they receive a cardiomyopathy diagnose&#xD;
&#xD;
          -  patients &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Göteborg University, Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>November 2, 2018</last_update_submitted>
  <last_update_submitted_qc>November 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Arrhythmogenic Right Ventricular Dysplasia</mesh_term>
    <mesh_term>Cardiomyopathy, Restrictive</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

